Intuitive Surgical draws fresh analyst attention, shares supported by long-term growth story

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 13:15.

Intuitive Surgical (US46120E6023) remains in focus on the NASDAQ as analysts continue to underline its long-term growth potential in robotic-assisted surgery. The stock is a constituent of the NASDAQ-100, and Piper Sandler has recently highlighted structural demand drivers for the company’s flagship robotic platform.

What analysts are saying

Piper Sandler pointed to Intuitive Surgical’s expanding procedure volumes and installed base as key long-term catalysts, noting that minimally invasive surgery remains a multi-year adoption trend in hospitals worldwide. The firm drew attention to Intuitive Surgical alongside other growth names, framing the company as a beneficiary of increasing utilization of robotic systems in core specialties.

Consensus data compiled by MarketBeat shows that Wall Street continues to view Intuitive Surgical positively, with a majority of analysts maintaining Buy or equivalent ratings on the shares. The average price target sits modestly above the latest close, indicating expectations for continued earnings expansion supported by volume growth rather than aggressive margin assumptions.

Valuation and expectations

According to TradingKey, Intuitive Surgical trades on a current price-earnings ratio of around 48.4, placing it toward the higher end of the Healthcare Equipment & Supplies peer group but below its own recent valuation peaks. The analysis notes that the P/E multiple is materially lower than historical extremes above 90, reflecting some normalization even as revenue and procedures trends remain robust.

MarketBeat’s data show Intuitive Surgical shares closing at 404.70 US dollars on NASDAQ on 2026-06-26, with a small after-hours uptick to 405.56 dollars later that evening. This level embeds the current valuation metrics and implies that investors continue to pay a premium for the company’s recurring revenue from instruments and accessories tied to each procedure.

The product behind the stock

Intuitive Surgical generates its revenues primarily from the da Vinci surgical system, a robotic-assisted platform used in procedures such as prostatectomies, hysterectomies and colorectal surgeries. The business model combines capital sales of the systems with recurring revenue from instruments, accessories and service contracts tied to every procedure performed on installed systems.

Where the shares trade today

The Intuitive Surgical shares (US46120E6023) last closed on NASDAQ on 2026-06-26 at 404.70 US dollars, with extended trading data showing a subsequent print at 405.56 dollars later the same day.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any kind. All data are based on sources believed to be reliable as of the stated dates but may change without notice.